Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

apceth Starts Commercial Manufacturing of Zynteglo™ ▼, bluebird bio’s Gene Therapy for Transfusion-Dependent β-Thalassemia

b3cnewswireJanuary 17, 2020

Tag: apceth , bluebird bio , Zynteglo

PharmaSources Customer Service